Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | R505C |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | FBXW7 R505C lies within WD repeat 4 of the Fbxw7 protein (UniProt.org). R505C results in ubiquitination and degradation of Braf similar to wild-type Fbxw7 in cultured cells (PMID: 32907612), but confers a loss of function to Fbxw7 as indicated by a loss of binding to NICD in cell culture (PMID: 17646409), impaired degradation of NICD, resulting in increased activity in a luciferase assay (PMID: 27247421), failure to degrade cyclin E, c-Myc, and Mcl1 in cell culture (PMID: 32907612), aberrant subnuclear localization (PMID: 30510140), and impaired degradation of Klf5 in cell culture (PMID: 28963353). |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 R505C |
Transcript | NM_033632.3 |
gDNA | chr4:g.152326137G>A |
cDNA | c.1513C>T |
Protein | p.R505C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_033632 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
NM_001349798.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.152326137G>A | c.1513C>T | p.R505C | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|